Study Flaws, Data Integrity Issues Clog China Review System As Applications Soar

Total Filings Processed Up 33%

 
• By Brian Yang
  
China growth
CHINA NEW DRUG FILINGS SOAR BUT DATA AND STUDY ISSUES REMAIN • Source: Alamy

More from Approval Standards

More from Pathways & Standards